Abdominal Aortic Aneurysm Screening — CPB 0702 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0702 governing abdominal aortic aneurysm screening, effective December 20, 2025. The update explicitly designates AI-assisted AAA screening tools and several emerging diagnostic approaches as experimental — and your billing team needs to know which codes are now in the crosshairs.

Aetna's AAA screening coverage policy under CPB 0702 Aetna system has always been narrow. One patient population, one covered indication, one covered CPT code (76706) when selection criteria are met. What this December 2025 update adds is a formal list of non-covered technologies — including artificial intelligence tools for AAA screening, CPT 81270 for JAK2V617F gene analysis, CCR2 PET/CT imaging, and m6A methylation evaluation. If your vascular surgery, radiology, or primary care billing teams are experimenting with any of these newer approaches on Aetna patients, stop and read this before submitting another claim.

Quick-Reference Table

Aetna Abdominal Aortic Aneurysm Screening Coverage Criteria and Medical Necessity Requirements 2025

Aetna's AAA screening coverage policy is about as narrow as it gets. Exactly one indication meets medical necessity criteria: a one-time ultrasound screening for abdominal aortic aneurysms in men aged 65 or older.

That's it. No age range, no smoking history requirement, no family history pathway. Men 65 and older, one-time screen, done. Every other indication Aetna considers experimental, investigational, or unproven.

When this indication is met, CPT 76706 — ultrasound of the abdominal aorta, real time with image documentation, screening study — is the covered code. Use Z13.6 (encounter for screening for cardiovascular disorders, including AAA) as your primary diagnosis code. That pairing is your clean claim.

Prior authorization requirements aren't explicitly called out in the CPB 0702 policy text, but that doesn't mean your Aetna contracts are silent on it. Check your specific plan agreements before scheduling. Reimbursement for CPT 76706 is generally straightforward when the patient meets criteria — the medical necessity documentation is simple because the criteria are simple.

The real risk in this policy isn't the covered indication. It's the list of things Aetna just formally said they won't pay for.

Aetna AAA Screening Exclusions and Non-Covered Indications

The December 2025 update to CPB 0702 is largely about what Aetna won't cover. Five categories now carry an explicit experimental, investigational, or unproven designation.

AI-assisted AAA screening and planning. This is the headline addition. Aetna now formally excludes artificial intelligence tools used for AAA screening and identification — including AI prediction of AAA growth and rupture, AI-assisted pre-operative planning and endograft sizing, and AI prediction of post-operative outcomes following endovascular aneurysm repair (EVAR). This covers a broad swath of the AI-in-vascular-imaging market. If your practice uses any vendor software with AI-driven AAA analysis on Aetna patients, that service is not billable as a separate charge under this policy.

JAK2V617F screening (CPT 81270). Aetna excludes two JAK2-related screening applications. First, screening JAK2V617F-positive individuals (those with a known myeloproliferative disorder marker) for ascending aortic aneurysms. Second, screening patients with large ascending aneurysms for the JAK2V617F sequence variation using CPT 81270. Both directions of that clinical question — starting with JAK2 and looking for aneurysm, or starting with aneurysm and looking for JAK2 — are excluded. The ICD-10 codes I71.11 and I71.21 (ascending aortic aneurysm, ruptured and without rupture) are in the code set but don't generate coverage here.

CCR2 PET/CT screening. C-C chemokine receptor type 2 PET/CT for AAA screening is experimental. This is an emerging molecular imaging approach, not yet in widespread clinical use, but worth flagging if your facility participates in research protocols.

m6A methylation evaluation. Evaluation of N6-methyladenosine methylation for AAA diagnosis and prognosis is experimental. Again, this is largely a research-stage technology, but the explicit designation matters if your lab or research partners are trying to bill for it.

The pattern here is clear. Aetna is drawing a hard line between the established, guideline-supported one-time ultrasound screen and everything that's come out of the research pipeline in the last several years. The AI exclusion is the one most likely to affect your billing team right now.

Coverage Indications at a Glance

Aetna AAA Screening Billing Guidelines and Action Items 2025

The effective date for this update is December 20, 2025. Here's what your billing team should do now.

1. Audit your active Aetna AAA claims for CPT 81270.
If you have any pending or recently submitted claims pairing CPT 81270 (JAK2 gene analysis) with an AAA or ascending aortic aneurysm diagnosis on an Aetna patient, review them immediately. Claim denial risk under CPB 0702 is high for this pairing. Pull claims with ICD-10 codes I71.11, I71.21, I71.30–I71.33, or I71.40–I71.43 and cross-reference any 81270 billing.

2. Confirm CPT 76706 is your primary screening code — not 76770 or 76775.
CPT 76706 is the screening-specific code for abdominal aortic ultrasound. CPT 76770 (retroperitoneal ultrasound, complete) and CPT 76775 (retroperitoneal ultrasound, limited) are in the policy as related codes but don't carry the same covered screening designation. If your coders are defaulting to 76770 or 76775 for AAA screening encounters, that's a medical necessity documentation problem waiting to happen.

3. Check your AI imaging vendor contracts for separate billing exposure.
If your radiology group or vascular practice uses AI software that auto-generates AAA measurements, rupture risk scores, or endograft sizing recommendations, find out whether you're currently billing a separate line item for that service on Aetna claims. Under CPB 0702, that charge is experimental. Flag it with your compliance officer before your next billing cycle.

4. Verify patient eligibility criteria before scheduling.
The covered population is men aged 65 or older. That's the only group where CPT 76706 is medically necessary under this policy. Build that age-and-sex check into your scheduling workflow if it isn't already there. A claim denial on a 64-year-old male or any female patient is entirely avoidable.

5. Update your ICD-10 pairing templates for Z13.6.
Z13.6 (encounter for screening for cardiovascular disorders, including AAA) is your diagnosis code for covered screenings. Make sure your charge capture templates for AAA screening visits default to Z13.6 paired with CPT 76706. Review the full F17.210–F17.219 nicotine dependence code range too — those codes are in the CPB 0702 code set, likely reflecting historical smoking history documentation patterns. Confirm with your compliance officer whether nicotine dependence codes should appear as secondary diagnoses on your Aetna AAA screening claims.

6. Don't bill CPT 76706 more than once per patient.
The policy is explicit: this is a one-time screening. If a patient has a prior claim history for CPT 76706 with Aetna, a repeat screening claim will deny. Check patient history before the encounter.

CPT, HCPCS, and ICD-10 Codes for Abdominal Aortic Aneurysm Screening Under CPB 0702

Covered CPT Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 0702

These codes appear in the policy but are not designated as the primary covered screening code. Use with caution and confirm documentation supports the specific code billed.

Not Covered / Experimental CPT Codes

Key ICD-10-CM Diagnosis Codes

A note on the nicotine dependence codes: F17.210–F17.219 and Z87.891 appear in the CPB 0702 code set without an explicit group label. This likely reflects Aetna's recognition that smoking history is clinically relevant to AAA risk, even though it isn't a separate coverage criterion in this policy. Don't use these as primary diagnosis codes on AAA screening claims. If you're unsure how to use them as secondary codes in your Aetna billing workflow, loop in your compliance officer before the December 20, 2025 effective date passes and live claims start flowing.

One more thing worth saying plainly: the AI exclusion in this update reflects a pattern you'll see across payers in 2026. Aetna is not the only insurer formalizing AI-assisted imaging as experimental. If your practice is making capital investment decisions around AI vascular imaging tools based on expected reimbursement, this CPB 0702 update is a data point you need to share with your medical director and finance team now.